NCT05270096Recruiting
International Leukemia Target Board
International Concerted Action to Allocate Children, Adolescents and Young Adults With Relapsed and Refractory Leukemia/Lymphoma to the Right Therapy.
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician. The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level. As such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 15 Feb 2022
- Start date
- 31 Dec 2022
- Primary completion date
- 1 Jul 2030
- Lead sponsor
- Princess Maxima Center for Pediatric Oncology
- Diseases
- Childhood cancers
- NCT number
- NCT05270096
What you commit to
- Study type: Observational
- Planned participants: 600
- From 31 Dec 2022 to the primary completion date, 1 Jul 2030
- 7 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- The patient has been diagnosed with a R/R hematological malignancy;
- The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy;
- The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment;
- The patients' life expectancy is at least 6 weeks;
- The patient has undergone any sort of molecular profiling of his/her tumor and the re-sults of this analysis are available;
- The patient has undergone flow cytometry in a certified lab and results are available;
- Written informed consent of patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained.
Age in the registry: 0 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UH Gent Coordinator of this site? Confirm its status | Ghent | Belgium | Recruiting |
| Righospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
| Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Newcastle Hospital Coordinator of this site? Confirm its status | Newcastle | United Kingdom | Recruiting |
| Semmelweis Coordinator of this site? Confirm its status | Budapest | Hungary | Recruiting |
| Princess Máxima Center for Pediatric Oncology Coordinator of this site? Confirm its status | Utrecht | Netherlands | Recruiting |
| Queen Silvia Coordinator of this site? Confirm its status | Gothenburg | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.